AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

Stocks Yahoo Finance By Yahoo Finance 22 Jun 2026 22:56 1 min read

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

Read the full story on Yahoo Finance → Opens the original article on finance.yahoo.com

Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.